Episode 35:2 Stocks With Fantastic Compound Growth Potential, and 1 Stock That May Not Be Long For This World

Episode 35:2 Stocks With Fantastic Compound Growth Potential, and 1 Stock That May Not Be Long For This World

Synopsys is a leader in EDA (electronic design automation) software and has had great growth over the past decade. The company will have a new CEO in 2024, one that has been at Synopsys for decades. Synopsys also has a segment focusing on software verification and security. What do these changes mean for the company and is it a stock you should be interested in learning about? Palo Alto Networks has been under CEO Nikesh Arora for 5 years now, and has certainly turned things around. Palo Alto Networks has gone from a traditional hardware-based company to a full-blown software-based platform with AI (security automation) woven throughout its services. While the stock isn’t cheap, is it worth considering as a top cybersecurity buy? Sentinelone is a small-cap stock that we had added to our small-cap basket earlier this year, and it's looking like SentinelOne may not be there for much longer. Reports emerged the high-growth endpoint cybersecurity business has itself for sale. Why? The answer reveals an investing risk that is often overlooked. All this and more discussed in this episode of Chip Stock Investor! ☕☕☕If you feel so inclined, please show your support here by fueling our caffeine addiction 👇 https://ko-fi.com/chipstockinvestor

Content in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. Nicholas and Kasey Rossolillo owns shares Synopsys, Palo Alto Networks & SenitnelOne

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(492)

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's st...

17 Syys 14min

The Fastest-Growing Chip Stock Is Also the Most Hated

The Fastest-Growing Chip Stock Is Also the Most Hated

We compare Credo (CRDO) against Broadcom (AVGO), Marvell (MRVL), and Astera Labs (ALAB) on revenue growth, gross margin, operating margin, and free cash flow margin — four fabless companies selling in...

15 Syys 13min

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

We break down the takeaways from Oracle's (ORCL) Q1 fiscal 2027 earnings call — what to expect through 2026 and into 2027–2028 as hyperscaler CapEx stays high but is set to slow in growth by 2027, and...

14 Syys 12min

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia just proposed its largest acquisition ever — $12.9 billion for Hugging Face. But regulators in the US, EU, and China may have other plans.Nvidia has announced plans to acquire Hugging Face, the...

10 Syys 15min

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage just rebranded to Everpure — and in the same stretch, free cash flow went negative 20% in a single quarter. Here's what's really going on.Pure Storage has officially rebranded as Everpure...

10 Syys 19min

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept BioRobotics is down roughly 80% from its 2025 highs but the technology behind its Aquablation system genuinely works. So why won't we put PRCT in our portfolio?Procept (PRCT) has one of the mo...

10 Syys 28min

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers.Oscar Health (OSCR) just posted stro...

10 Syys 11min

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Networks (PANW) has been flying high into the end of FY2026. After a decade-long 1,400% run — capped by a broader cybersecurity rally following the Anthropic "Mythos moment" in early 2026 — ...

2 Syys 14min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
rss-rahapodi
psykopodiaa-podcast
mimmit-sijoittaa
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
rss-paasipodi
oppimisen-psykologia
rss-karon-grilli
rss-inderes
rss-rahamania
rss-sami-miettinen-neuvottelija
rss-startup-ministerio
lakicast
rss-pinnan-alle
rss-siksi-viestinta
pomojen-suusta
rss-seuraava-potilas
rahapuhetta